Fox G A, Paterson N A, McCormack D G
A. C. Burton Vascular Biology Laboratory, Victoria Hospital Research Institute, London, Ontario, Canada.
J Cardiovasc Pharmacol. 1996 Jul;28(1):30-5. doi: 10.1097/00005344-199607000-00006.
We postulated that the attenuated pulmonary and systemic vascular contractility observed in sepsis was secondary to the release of vasodilator prostaglandins. We used the cyclooxygenase inhibitor meclofenamate to inhibit prostaglandin synthesis in an unanesthetized, chronically instrumented model of hyperdynamic sepsis. Sixteen male Sprague-Dawley rats (300-350 g) were randomized to either sepsis induced by cecal ligation and perforation (CLP, n = 8) or a sham procedure (Sham, n = 8). Vascular reactivity was assessed by measuring the hypoxic (FiO2 = 0.08) pulmonary pressor response (HPV), and the systemic pressor response to an intravenous infusion of phenylephrine (1.5-7.5 micrograms/kg/min) before and after the administration of meclofenamate (5 mg/kg intravenously, i.v.). Twenty-four hours postoperatively, CLP animals had significantly increased cardiac output (CO) as compared with Sham animals (204 +/- 12 vs. 148 +/- 5 ml/min, p < 0.05), slightly decreased mean arterial pressure (MAP) (109 +/- 4 vs. 118 +/- 3 mm Hg, p < 0.05), and decreased total systemic vascular resistance (TSVR) (0.546 +/- 0.046 vs. 0.805 +/- 0.030 mm Hg.min.ml-1, p < 0.05). Mean pulmonary artery pressure (MPAP) and total pulmonary vascular resistance (TPVR) were similar in both groups (p > 0.05). In response to hypoxia, the change in MPAP (delta MPAP) was 3.6 +/- 1.0 and 6.9 +/- 0.8 (mm Hg) in CLP and Sham animals, respectively (p < 0.05). Similarly, the change in TPVR (delta TPVR) during hypoxia was 0.012 +/- 0.006 and 0.038 +/- 0.009 mm Hg.min.ml-1 in CLP and Sham (p < 0.05). The pulmonary and systemic blood pressure (BP) response to phenylephrine was also attenuated in CLP as compared with Sham animals. After treatment with meclofenamate, differences were no longer apparent in the HPV response between CLP and Sham animals, due to a slight increase in the HPV response of CLP animals and a slight decrease in the HPV response in Sham animals. The attenuated pressor response to phenylephrine was not changed in either the pulmonary or the systemic circulation after the administration of meclofenamate. These data suggest that vasodilator prostaglandins may contribute to the attenuated pulmonary pressor response in sepsis. However, the mechanism of the attenuated HPV may be different than the attenuated response to exogenous catecholamines since meclofenamate had no effect on either the pulmonary or systemic response to a phenylephrine infusion in septic animals.
我们推测,脓毒症中观察到的肺血管和全身血管收缩力减弱是血管舒张性前列腺素释放的结果。我们使用环氧化酶抑制剂甲氯芬那酸,在未麻醉、长期植入监测装置的高动力型脓毒症模型中抑制前列腺素合成。将16只雄性Sprague-Dawley大鼠(300 - 350克)随机分为盲肠结扎穿孔诱导脓毒症组(CLP,n = 8)或假手术组(Sham,n = 8)。在静脉注射甲氯芬那酸(5毫克/千克,静脉注射)前后,通过测量低氧(FiO2 = 0.08)肺血管加压反应(HPV)以及静脉输注去氧肾上腺素(1.5 - 7.5微克/千克/分钟)时的全身血管加压反应来评估血管反应性。术后24小时,与假手术组动物相比,CLP组动物的心输出量(CO)显著增加(204 ± 12 vs. 148 ± 5毫升/分钟,p < 0.05),平均动脉压(MAP)略有降低(109 ± 4 vs. 118 ± 3毫米汞柱,p < 0.05),总全身血管阻力(TSVR)降低(0.546 ± 0.046 vs. 0.805 ± 0.030毫米汞柱·分钟·毫升-1,p < 0.05)。两组的平均肺动脉压(MPAP)和总肺血管阻力(TPVR)相似(p > 0.05)。对低氧的反应中,CLP组和假手术组动物的MPAP变化(ΔMPAP)分别为3. ± 1.0和6.9 ± 0.8(毫米汞柱)(p < 0.05)。同样,低氧期间CLP组和假手术组的TPVR变化(ΔTPVR)分别为0.012 ± 0.006和0.038 ± 0.009毫米汞柱·分钟·毫升-1(p < 0.05)。与假手术组动物相比,CLP组动物对去氧肾上腺素的肺和全身血压(BP)反应也减弱。用甲氯芬那酸治疗后,CLP组和假手术组动物在HPV反应上的差异不再明显,这是由于CLP组动物的HPV反应略有增加,而假手术组动物的HPV反应略有降低。给予甲氯芬那酸后,肺循环或体循环中对去氧肾上腺素减弱的加压反应均未改变。这些数据表明,血管舒张性前列腺素可能导致脓毒症中肺血管加压反应减弱。然而,HPV减弱的机制可能与对外源性儿茶酚胺反应减弱的机制不同,因为甲氯芬那酸对脓毒症动物肺或体循环中对去氧肾上腺素输注的反应均无影响。